Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 7, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

November 30, 2010

Conditions
Advanced Solid TumorsLymphoma
Interventions
DRUG

VTX-2337

Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.

Trial Locations (2)

Unknown

Mayo Clinic, Scottsdale

Scottsdale Healthcare, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY